Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RXRX Stock Price Chart Interactive Chart >
RXRX Price/Volume Stats
| Current price | $8.08 | 52-week high | $42.81 |
| Prev. close | $8.25 | 52-week low | $4.92 |
| Day low | $8.04 | Volume | 676,900 |
| Day high | $8.49 | Avg. volume | 1,132,579 |
| 50-day MA | $6.54 | Dividend yield | N/A |
| 200-day MA | $13.03 | Market Cap | 1.38B |
Recursion Pharmaceuticals Inc. (RXRX) Company Bio
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Latest RXRX News From Around the Web
Below are the latest news stories about Recursion Pharmaceuticals Inc that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapitalIn this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […] |
Yong Rong (HK) Asset Management Ltd Buys Futu Holdings, XPeng Inc, Pinduoduo Inc, Sells ...Investment company Yong Rong (HK) Asset Management Ltd (Current Portfolio) buys Futu Holdings, XPeng Inc, Pinduoduo Inc, Taiwan Semiconductor Manufacturing Co, Luckin Coffee Inc, sells Advanced Micro Devices Inc, Freeport-McMoRan Inc, Marathon Digital Holdings Inc, Affirm Holdings Inc, Recursion Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Yong Rong (HK) Asset Management Ltd. |
Recursion to Participate in Upcoming Investor ConferencesRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: |
Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and Recursion Pharmaceuticals (RXRX)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Omeros (OMER – Research Report) and Recursion Pharmaceuticals (RXRX – Research Report). Omeros (OMER) In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Omeros. The company's shares closed last Tuesday at $7.60, close to its 52-week low of $5.45. According to TipRanks. |
RXRX Price Returns
| 1-mo | N/A |
| 3-mo | 12.85% |
| 6-mo | -52.83% |
| 1-year | -78.34% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.83% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...